Vical Announces Key International Patents for Vaxfectin® Adjuvant
19-Sep-2011
|
Source :
|
Visits : 8499
SAN DIEGO - Vical Incorporated announced in a press release the issuance of Canadian Patent No. 2,365,416 and Japanese Patent No. 4,800,485 covering Vical's novel cationic lipid/co-lipid adjuvant, Vaxfectin®. Specific claims include composition of the Vaxfectin® adjuvant, composition of Vaxfectin®-formulated vaccines, and methods for their use. The new patents add to Vical's existing US and European patent coverage for Vaxfectin® and to Vical's family of core technology patents broadly covering gene-based vaccines and therapeutics.
"We are pleased to extend patent coverage of our Vaxfectin® adjuvant to the important Canadian and Japanese markets," said Vijay B. Samant, Vical's President and Chief Executive Officer.
"Vaxfectin® was discovered through extensive screening of Vical's lipid portfolio, and represents the best-performing among this new class of adjuvants which can be used for both conventional and DNA vaccines. We have a growing library of research documenting its use with a variety of infectious diseases and cancer applications. We have successfully demonstrated the adjuvant's tolerability in three Phase 1 clinical trials with Vaxfectin®-formulated vaccines against pandemic strains of influenza."
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor.